Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
98 hedge funds and large institutions have $146M invested in Aratana Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 18 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 32
8% less funds holding
Funds holding: 107 → 98 (-9)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
28% less capital invested
Capital invested by funds: $204M → $146M (-$58.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
93% less call options, than puts
Call options by funds: $310K | Put options by funds: $4.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.76M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.59M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$1.38M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$2.94M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.78M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.43M |
| 4 |
Jennison Associates
New York
|
-$1.16M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.16M |
PETX Hedge Fund Activity: Q1 2017 in Review
98 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q1 2017, worth a combined $146M — down 28% from $204M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PETX and 16 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 34 added.
The largest buyer was BlackRock, adding an estimated $17.9M. The largest seller was First Light Asset Management, exiting entirely with an estimated $2.94M sold.
- 98 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q1 2017, down from 107 in Q4 2016.
- Funds reported $146M of Aratana Therapeutics, Inc. stock for Q1 2017, down 28% quarter-over-quarter.
- 16 funds opened new Aratana Therapeutics, Inc. positions in Q1 2017 and 18 closed out, a net change of -2 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $17.9M added.
- The largest Aratana Therapeutics, Inc. seller in Q1 2017 was First Light Asset Management, an estimated $2.94M sold.
Based on aggregated 13F filings for Q1 2017.